Empirico’s core product is its Precision Insights Platform, a human genetics‑focused discovery platform that combines a large curated biological dataset with statistical and machine‑learning algorithms to generate and prioritize therapeutic hypotheses. The platform pairs in silico target discovery with experimental validation to elucidate mechanisms by which genetic variation impacts disease and to identify appropriate therapeutic modalities. Empirico has active preclinical programs across immune, dermatological, cardiometabolic, and ophthalmic indications based on targets from the platform. The company announced a strategic three‑year collaboration with Ionis to identify targets amenable to antisense oligonucleotide therapeutics and to incorporate human genetics evidence into Ionis’s ongoing programs for target validation, indication and biomarker selection, and patient stratification. Financially, Ionis made a $10 million equity investment in Empirico and the company closed a $17 million Series A‑2 financing; Empirico also raised a $12.5 million Series A in November 2018. Under the collaboration Empirico is eligible to receive over $620 million in clinical, regulatory and commercial milestones plus royalties, and may receive additional near‑term commitments from Ionis of up to $30 million tied to operational and preclinical milestones.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2020